Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis

Richard P. McQuellon, Brian W. Loggie, Anna B. Lehman, Gregory B. Russell, Ronald A. Fleming, Perry Shen, Edward A. Levine

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Background: Cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis is used as a palliative treatment for a variety of malignancies. The purpose of this study was to measure the quality of life (QOL) of survivors (>3 years) after treatment. Methods: Patients were interviewed by telephone with the following tools: (1) the Functional Assessment of Cancer Therapy-Colon (FACT-C), (2) the Short Form of the Medical Outcomes Study Questionnaire, (3) the Center for Epidemiologic Studies-Depression scale, (4) the Life Appreciation scale, (5) the Psychosocial Concerns Questionnaire, and (6) performance status rating. Results: Seventeen (10 appendix, 5 large intestine, 1 ovarian, and 1 peritoneum) of 109 patients were interviewed from 3.1 to 8.0 years after treatment. Ten patients (62.5%) described their health as excellent or very good. No limitations on moderate activity were reported in 94% of cases. Paired t-tests were used to compare 10 patients who had baseline QOL data. FACT mean difference scores and P values (positive difference scores indicate improved QOL) were functional well-being: 4.9, P = .01; physical well-being: 3.3, P = .05; and FACT total: 14.3, P = .02. Conclusions: Long-term survival with good QOL is possible for selected patients with peritoneal carcinomatosis after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy.

Original languageEnglish
Pages (from-to)155-162
Number of pages8
JournalAnnals of Surgical Oncology
Volume10
Issue number2
DOIs
StatePublished - 2003

Fingerprint

Survival Rate
Quality of Life
Carcinoma
Drug Therapy
Peritoneum
Large Intestine
Appendix
Mitomycin
Palliative Care
Telephone
Colonic Neoplasms
Survivors
Epidemiologic Studies
Therapeutics
Outcome Assessment (Health Care)
Survival
Health
Neoplasms
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Oncology
  • Surgery

Cite this

Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. / McQuellon, Richard P.; Loggie, Brian W.; Lehman, Anna B.; Russell, Gregory B.; Fleming, Ronald A.; Shen, Perry; Levine, Edward A.

In: Annals of Surgical Oncology, Vol. 10, No. 2, 2003, p. 155-162.

Research output: Contribution to journalArticle

McQuellon, Richard P. ; Loggie, Brian W. ; Lehman, Anna B. ; Russell, Gregory B. ; Fleming, Ronald A. ; Shen, Perry ; Levine, Edward A. / Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. In: Annals of Surgical Oncology. 2003 ; Vol. 10, No. 2. pp. 155-162.
@article{82f8872d94684043b549bb8b171275b8,
title = "Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis",
abstract = "Background: Cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis is used as a palliative treatment for a variety of malignancies. The purpose of this study was to measure the quality of life (QOL) of survivors (>3 years) after treatment. Methods: Patients were interviewed by telephone with the following tools: (1) the Functional Assessment of Cancer Therapy-Colon (FACT-C), (2) the Short Form of the Medical Outcomes Study Questionnaire, (3) the Center for Epidemiologic Studies-Depression scale, (4) the Life Appreciation scale, (5) the Psychosocial Concerns Questionnaire, and (6) performance status rating. Results: Seventeen (10 appendix, 5 large intestine, 1 ovarian, and 1 peritoneum) of 109 patients were interviewed from 3.1 to 8.0 years after treatment. Ten patients (62.5{\%}) described their health as excellent or very good. No limitations on moderate activity were reported in 94{\%} of cases. Paired t-tests were used to compare 10 patients who had baseline QOL data. FACT mean difference scores and P values (positive difference scores indicate improved QOL) were functional well-being: 4.9, P = .01; physical well-being: 3.3, P = .05; and FACT total: 14.3, P = .02. Conclusions: Long-term survival with good QOL is possible for selected patients with peritoneal carcinomatosis after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy.",
author = "McQuellon, {Richard P.} and Loggie, {Brian W.} and Lehman, {Anna B.} and Russell, {Gregory B.} and Fleming, {Ronald A.} and Perry Shen and Levine, {Edward A.}",
year = "2003",
doi = "10.1245/ASO.2003.03.067",
language = "English",
volume = "10",
pages = "155--162",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis

AU - McQuellon, Richard P.

AU - Loggie, Brian W.

AU - Lehman, Anna B.

AU - Russell, Gregory B.

AU - Fleming, Ronald A.

AU - Shen, Perry

AU - Levine, Edward A.

PY - 2003

Y1 - 2003

N2 - Background: Cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis is used as a palliative treatment for a variety of malignancies. The purpose of this study was to measure the quality of life (QOL) of survivors (>3 years) after treatment. Methods: Patients were interviewed by telephone with the following tools: (1) the Functional Assessment of Cancer Therapy-Colon (FACT-C), (2) the Short Form of the Medical Outcomes Study Questionnaire, (3) the Center for Epidemiologic Studies-Depression scale, (4) the Life Appreciation scale, (5) the Psychosocial Concerns Questionnaire, and (6) performance status rating. Results: Seventeen (10 appendix, 5 large intestine, 1 ovarian, and 1 peritoneum) of 109 patients were interviewed from 3.1 to 8.0 years after treatment. Ten patients (62.5%) described their health as excellent or very good. No limitations on moderate activity were reported in 94% of cases. Paired t-tests were used to compare 10 patients who had baseline QOL data. FACT mean difference scores and P values (positive difference scores indicate improved QOL) were functional well-being: 4.9, P = .01; physical well-being: 3.3, P = .05; and FACT total: 14.3, P = .02. Conclusions: Long-term survival with good QOL is possible for selected patients with peritoneal carcinomatosis after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy.

AB - Background: Cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis is used as a palliative treatment for a variety of malignancies. The purpose of this study was to measure the quality of life (QOL) of survivors (>3 years) after treatment. Methods: Patients were interviewed by telephone with the following tools: (1) the Functional Assessment of Cancer Therapy-Colon (FACT-C), (2) the Short Form of the Medical Outcomes Study Questionnaire, (3) the Center for Epidemiologic Studies-Depression scale, (4) the Life Appreciation scale, (5) the Psychosocial Concerns Questionnaire, and (6) performance status rating. Results: Seventeen (10 appendix, 5 large intestine, 1 ovarian, and 1 peritoneum) of 109 patients were interviewed from 3.1 to 8.0 years after treatment. Ten patients (62.5%) described their health as excellent or very good. No limitations on moderate activity were reported in 94% of cases. Paired t-tests were used to compare 10 patients who had baseline QOL data. FACT mean difference scores and P values (positive difference scores indicate improved QOL) were functional well-being: 4.9, P = .01; physical well-being: 3.3, P = .05; and FACT total: 14.3, P = .02. Conclusions: Long-term survival with good QOL is possible for selected patients with peritoneal carcinomatosis after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0038622008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038622008&partnerID=8YFLogxK

U2 - 10.1245/ASO.2003.03.067

DO - 10.1245/ASO.2003.03.067

M3 - Article

VL - 10

SP - 155

EP - 162

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -